The Cat Health Company

What The Cat Health Company does

The Cat Health Company is a Bucharest-based biotechnology startup founded in 2024 that develops longevity therapeutics for companion cats, targeting age-related conditions including sarcopenia, chronic kidney disease, and neurodegeneration. The company employs in silico drug discovery methods, using proprietary state-of-the-art machine learning models combined with terabytes of novel omic data collected from diseased, healthy, young, and elderly cats to design and optimize evidence-based medicines that address the molecular mechanisms of feline aging. Earlier versions of the company's software have been published open-source in Cell and Nature family journals, providing academic validation of the underlying methodology while the current generation of models is held under trade secret.

The company is currently conducting clinical studies in the European Union with companion cats aged 10 and older, supported by a network of partner veterinary clinics in Bucharest and surrounding areas. Cat owners enroll their senior cats through the company's website for clinical study participation at no cost, while partner veterinarians perform examinations, blood draws, and ongoing monitoring. A core team of five members (CEO, COO, clinical lead, scientist, legal counsel) plus three advisors covers drug discovery, veterinary medicine, cellular senescence research (Buck Institute for Aging), and regulatory matters.

The Cat Health Company is pre-revenue and in clinical trial phase. Cumulative funding to date is approximately $1.7 million, comprising a €500,000 pre-seed round led by Early Game Ventures in October 2024 and a $1.2 million seed round in October 2025 with Early Game Ventures, Portfolia's Active Aging & Longevity Fund II, and 100 Plus Capital. Future revenue is expected from regulatory-approved longevity medicines for cats, with regulatory submissions targeted for early 2026 and clinical trial results expected during 2026.

Name

The Cat Health Company

Legal name

The Cat Health Company S.R.L.

Website

https://thecathealth.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

The Cat Health Company is a Bucharest-based biotech startup developing longevity therapeutics for senior companion cats, using proprietary machine learning models and feline omic data to target sarcopenia, chronic kidney disease, and neurodegeneration in clinical trials across the European Union.

Ownership category

akta.pro rank

Product category

Veterinary Biotech / Feline Longevity Therapeutics

NAICS

Veterinary Services (541940)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Senior & Cognitive Support Supplements (HLAMALAJ)

akta.pro secondary industry

Urinary & Kidney Support Supplements (HLAMALAI)

Keywords

• Feline longevity therapeutics
• Veterinary biotech research
• Companion animal health
• Age-related disease treatment
• Computational drug design

Headquarters

HQ city

Bucharest

HQ country

Romania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Longevity Therapeutics for Cats: Pre-revenue biotech company in clinical trial stage. Developing therapeutics to extend cat lifespans and healthspan. Expected to generate revenue through FDA/regulatory-approved longevity medicines for cats once clinical trials complete in 2026.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

The Cat Health Company designs and develops longevity therapeutics for companion cats, using computational modeling, machine learning algorithms, and in silico prediction to create evidence-based medicines that target molecular mechanisms of aging. Its pipeline focuses on sarcopenia, chronic kidney disease (CKD), and neurodegeneration, with clinical studies conducted in the European Union on cats aged 10 and older and regulatory submissions targeted for early 2026.

Product overview

The Cat Health Company is developing longevity medicines for cats as a unified product offering centered around their therapeutic pipeline. Their core product consists of advanced therapeutic programs targeting age-related conditions (sarcopenia, CKD, neurodegeneration) using in silico research methods and state-of-the-art ML models. The company supports its therapeutics through a clinical study program enrolling companion cats aged 10+ in the EU, and a veterinary clinical network that provides real-world clinical validation and trial participation infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

• Longevity Therapeutics Pipeline Advanced therapeutic programs designed to target conserved mammalian pathways involved in age-related decline in cats, with focus on sarcopenia, chronic kidney disease (CKD), and neurodegeneration. Designed using in silico research methods with SOTA ML models and laboratory validations, with some programs reaching clinical stages.
• Feline Longevity Medicines Longevity medicines for cats intended to slow, pause, or reverse biological aging, delay disease onset, extend healthy lifespan, and improve quality of life in senior cats by targeting root causes of aging rather than symptoms.
• Clinical Study Program Clinical studies conducted in the European Union with companion cats aged 10 and older, including health screening, periodic checkups, and monitoring. Cats remain at home with their owners throughout the study.
• Veterinary Clinical Network A network of partner veterinary clinics in Bucharest and surrounding areas that participate in clinical trials. Veterinarians help identify eligible cats, perform exams, blood draws, and monitoring, with the company handling administrative support and study documentation.

Quantifiable outcome

• Extend healthy lifespan and improve quality of life in senior cats
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered major and minor.

• EpiPawsmajorStrategic or Co-development Partner · 3 October 2024Collaboration with EpiPaws on a study involving 100 cats to understand genes involved in feline aging. Joint research initiative supporting therapeutic development.
• Adrian Grosu (Novartis/Stonehaven)minorOthersExecutive advisor from Novartis and partner at Stonehaven, focused on the veterinary market.
• Sonia Arrison (100 Plus Capital)minorOthersSilicon Valley venture capital investor focused on biotech and longevity interventions serving as advisor.
• Florin Visa (Early Game VC)minorOthersPartner at Early Game VC with 20+ years of investing and advising on healthcare deals at EBRD, KPMG, Deloitte, ABN AMRO serving as advisor.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Vetoquinol: Vetoquinol is a global animal-health company with a meaningful companion-animal therapeutics portfolio, particularly in renal and chronic-care indications overlapping with TCHC's CKD target.
• Virbac: Virbac is a global animal-health pharmaceutical company with a companion-animal therapeutics portfolio that overlaps with the senior-cat care and chronic-condition indications TCHC is pursuing.
• Zoetis: Zoetis is the world's largest animal health company, with a broad portfolio of veterinary therapeutics across species. It is the dominant incumbent any successful veterinary biotech will eventually partner with or compete against for clinic relationships.
• Elanco Animal Health: Elanco is a top-tier global animal pharma company (recently expanded via the Dechra acquisition) with broad companion-animal therapeutics coverage. It represents the most likely strategic acquirer or partner for a niche player like TCHC at scale.
• IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics and practice-software company and is the principal channel through which companion-animal health innovation reaches US vet clinics. It overlaps with TCHC on the vet-clinic clinical-network angle.

Direct peers

• Loyal for Dogs: Loyal is developing FDA-regulated longevity drugs for senior dogs, the canine analogue of TCHC's feline work. It is the most directly comparable veterinary longevity biotech in market today, targeting the same age-related disease biology and the same regulatory pathway considerations.
• Rejuvenate Bio: Rejuvenate Bio is a veterinary biotech developing gene-therapy-based interventions targeting age-related diseases in companion animals. It overlaps with TCHC on the "treat the biology of aging in pets" thesis and on the senior pet end market.
• TriviumVet: TriviumVet is a veterinary biotech developing novel therapeutics for companion animals, with a comparable European footprint and stage. It competes for similar investor mindshare in the EU veterinary biotech niche.

Emerging players

• EpiPaws: EpiPaws is an epigenetic age-test company for pets and is TCHC's announced research partner on the 100-cat feline aging study. It overlaps on the feline longevity thesis but from a diagnostics/data perspective rather than therapeutics.
• Animal Biosciences: Animal Biosciences focuses on healthspan-extending therapeutics for companion animals, overlapping directly with TCHC's mission to extend healthy lifespan in senior pets through targeted intervention.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/the-cat-health-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Cat Health Company